Coordinated Open Data Will Drive Next-Level Health Research

An Interview With European Data Cohesion Experts ELIXIR

Experts from a European data sharing initiative talk to In Vivo about the importance of coordinated computational biology efforts for the future of life sciences innovation and the effective use of artificial intelligence.

ELIXIR
Katharina Lauer at an ELIXIR innovation and SME event • Source: ELIXIR Europe

ELIXIR, founded in December 2013, is a joint effort between several European countries for the development of coordinated, integrated and sustainable public bioinformatics services. “There are many public databases, software tools and training courses that already have extensive usage by academia and the life sciences industry. However, there is lot of fragmentation, so those resources don’t always work closely together,” Andrew Smith, ELIXIR’s head of external relations, told In Vivo. The group aims to better coordinate the evolution of bioinformatic services across those member countries.

ELIXIR has connected 22 countries. In each participating country there is a national effort to coordinate the public bioinformatics services. “Overall, across those 22 countries that are involved, we have 220 institutes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By 

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

 
• By 

Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.